Now Available: Spotlight on Alamar Biosciences CEO Yuling Luo. Click here to read.
RedShift BioAnalytics Inc. (RedShiftBioⓇ), a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in biomolecules, announced today the closing of its Series E Preferred Stock financing. The $20 million financing was led by Illumina Ventures and joined by all of the company’s current major investors, including Technology Venture ...
In honor of the 40th anniversary of Genetic Engineering & Biotechnology News, industry leaders in biotech and life sciences give their insights about the emergence of their industries over the last 40 years and what the future holds. Several of our portfolio companies are included in the piece: Sylvain Gariel (co-founder and CEO of DNA Script), Noah Nasser (CEO of Serimmune Inc.), and Emily ...
Walking Fish Therapeutics, a leader in B cell engineering, today announced the close of $50M Series A financing— led by investors including Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production. “Walking Fish’s financial backing, combined with its high...
Alamar Biosciences, Inc., a precision proteomics company that brings both ultra-high sensitivity and massively parallel scale to proteomic analysis, announced today that it has closed its $80 million Series B financing round, bringing its total funding to $110 million. “Alamar has made great strides in developing its novel technologies. This financing will position Alamar to complete the develo...
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
